Skip to main content
← All Companies
Eikon Therapeutics logo

Eikon Therapeutics

AI Augmented
AI Classification
Existing product enhanced with AI capabilities.

Drug discovery using advanced microscopy and computation

Total Funding

$350.7M

Founded

2019

Headquarters

Hayward, United States

Industry Vertical

Health & Biotech

Technology Segments

Drug DiscoveryBiotechnologyPrecision Medicine

About

Eikon Therapeutics is a biotechnology company founded in 2019 and headquartered in Hayward, California. It specializes in drug discovery and development by integrating Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to observe and measure protein dynamics in living cells. Eikon’s proprietary technologies enable the visualization of real-time biological processes, facilitating the development of breakthrough therapies for grievous illnesses such as cancer.

The company’s multidisciplinary team leverages automation and data science to accelerate the creation of innovative medicines, with operations spanning California, New Jersey, and New York.

Funding Rounds

1
DateRoundAmount
2025-02-26Series D$350.7M

Investors

13
Andreessen Horowitz Bio + HealthForesite CapitalThe Column GroupLux CapitalAlexandria Venture InvestmentsAME Cloud VenturesE15 VCGeneral CatalystSoros CapitalStepStone GroupFunds and accounts advised by T. Rowe Price AssociatesInc.Office of the Chief Investment Officer of the Regents of the University of California

Subscribe to Monday AI Signal

Weekly pre-seed and seed AI deal intelligence with early trends.